4DMedical Invests $3.4M in RevealDx for AI Lung Analysis

In a strategic move to enhance its cardiopulmonary imaging ecosystem, 4DMedical has injected $3.4 million into RevealDx. This investment is coupled with a global distribution pact that will see RevealDx's AI-powered lung nodule characterization software, RevealAI-Lung, reach new markets across the United States, Europe, Australia, and New Zealand.

The partnership signifies a significant step towards integrating advanced diagnostic tools into 4DMedical's existing platform, which already boasts functional imaging capabilities like CT:VQ for lung ventilation and perfusion analysis. By incorporating RevealAI-Lung, 4DMedical aims to offer a comprehensive solution that not only detects lung abnormalities but also assesses their malignancy potential, a critical advancement in early cancer detection.

RevealAI-Lung, which has secured regulatory approvals including FDA clearance in the U.S. and MDR certification in Europe, analyzes incidental lung nodules and generates a Malignancy Similarity Index (mSI). This metric assists radiologists in making more confident follow-up recommendations. The software's integration into the contextflow platform, an Austrian firm recently acquired by 4DMedical, is already demonstrating its utility in clinical settings across Europe.

This collaboration arrives at a time when AI in medical imaging is experiencing rapid adoption. The global AI in medical diagnostics market is projected to grow substantially, driven by the need for faster, more accurate diagnoses and the increasing volume of medical imaging data. RevealDx's technology, validated across over 1,500 patients and benchmarked against National Lung Screening Trial data, offers a compelling solution within this expanding sector.

Further bolstering its market potential, RevealAI-Lung is recognized for its reimbursement eligibility under U.S. Medicare codes 0721T and 0722T. This makes it the first medical imaging AI software to achieve reimbursement in both the U.S. and the European Union, a key factor for widespread clinical adoption and integration into standard care pathways. Studies suggest the technology can improve early cancer detection rates while mitigating false positives.

The strategic investment and distribution agreement underscore 4DMedical's commitment to building a connected network of cardiopulmonary care solutions. Following previous acquisitions of AI firms like Imbio in 2023, this latest move solidifies 4DMedical's position as a leader in leveraging AI for respiratory health. Chris Wood, CEO of RevealDx, highlighted the milestone's importance for earlier and more confident identification of potentially malignant nodules, while Andreas Fouras, Founder and CEO of 4DMedical, emphasized the vision of a connected ecosystem for cardiopulmonary care.